The NHLRC2 antibody targets the NHLRC2 protein, encoded by the *NHLRC2* gene, which belongs to the NHL repeat-containing protein family. NHLRC2 is hypothesized to function as an E3 ubiquitin ligase, playing a role in protein ubiquitination and degradation via the ubiquitin-proteasome system. While its exact biological mechanisms remain under investigation, NHLRC2 is linked to cellular processes such as protein quality control, stress response, and possibly tumor suppression.
Interest in NHLRC2 antibodies stems from their utility in studying NHLRC2's expression, localization, and interactions in diseases. Mutations in *NHLRC2* are associated with FINCA syndrome (Fibrosis, Neurodegeneration, and Cerebral Angiomatosis), a rare autosomal recessive disorder, making these antibodies critical for diagnostic and functional studies. Researchers employ NHLRC2 antibodies in techniques like Western blotting, immunohistochemistry, and immunofluorescence to explore its tissue distribution and dysregulation in pathological contexts, including cancer and neurodegenerative conditions.
Despite progress, many aspects of NHLRC2’s role remain unclear. Current studies focus on its involvement in ER-associated degradation (ERAD) and crosstalk with autophagy pathways. NHLRC2 antibodies also aid in validating experimental models, such as CRISPR-edited cell lines or animal models, to dissect disease mechanisms. Overall, NHLRC2 antibodies serve as essential tools for unraveling the protein’s contribution to cellular homeostasis and disease, with potential implications for therapeutic targeting.